紫杉醇
医学
卵巢癌
妇科肿瘤学
肿瘤科
内科学
化疗
不利影响
人口
癌症
环境卫生
作者
Maurie Markman,John A. Blessing,Stephen C. Rubin,Joseph P. Connor,Parviz Hanjani,Steven Waggoner
标识
DOI:10.1016/j.ygyno.2005.10.036
摘要
Abstract
Objective.
To evaluate the activity of single agent weekly paclitaxel in patients with both platinum and paclitaxel (delivered every 3 weeks)-resistant ovarian cancer. Methods.
Forty-eight patients with platinum and paclitaxel-resistant ovarian cancer (defined as progression during, or recurrence <6 months following, their prior treatment with both agents) received single agent weekly paclitaxel (80 mg/m2/week) until disease progression (assuming acceptable toxicity). Following the initial 12 weekly doses, treatment could be given for 3 weeks, with a 1 week break. Results.
In this chemoresistant population, the objective response rate was 20.9%. Serious adverse events were relatively uncommon (neuropathy-grade 2: 21%; grade 3: 4%; and grade 3 fatigue: 8%). Conclusion.
The weekly administration of paclitaxel can be a useful management approach in women with both platinum and paclitaxel (given every 3 weeks)-resistant ovarian cancer. It would be appropriate to directly compare weekly to every 3-week paclitaxel delivery in the setting of primary chemotherapy of advanced ovarian cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI